Pharmacogenomics discovery and implementation in genome-wide association studies era

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 5, Issue 1, 2013, Pages 1-9

  Ni, Xiuqin ^a,b   Zhang, Wei ^b   Huang, R Stephanie ^c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG CHOICE; EPIGENETICS; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; MEDICAL DECISION MAKING; MYOPATHY; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SEQUENCE ANALYSIS;

ANIMALS; CHROMOSOME MAPPING; DRUG DISCOVERY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS;

EID: 84871387256     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.1199     Document Type: Article

References (69)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279:1200-1205.
2. Kamali F, Wynne H. Pharmacogenetics of warfarin. Annu Rev Med 2010, 61:63-75.
3. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME. Pharmacogenomic discovery using cell-based models. Pharmacol Rev 2009, 61:413-429.
4. Zhang W, Dolan ME. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des 2009, 15:3782-3795.
5. Gamazon E, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A 2010, 107:9287-9292.
6. Colllins F, McKusick V. Implications of the Human Genome Project for medical science. JAMA 2001, 285:540-544.
7. International HapMap Consortium. The International HapMap Project. Nature 2003, 426:789-796.
8. International HapMap Consortium. A haplotype map of the human genome. Nature 2005, 437:1299-1320.
9. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073.
10. Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, Cheung VG. Common genetic variants account for differences in gene expression among ethnic groups. Nat Genet 2007, 39:226-231.
11. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, et al. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet 2008, 82:631-640.
12. Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, et al. Genetic architecture of transcript-level variation in humans. Am J Hum Genet 2008, 82:1101-1113.
13. Storey JD, Madeoy J, Strout JL, Wurfel M, Ronald J, Akey JM. Gene-expression variation within and among human populations. Am J Hum Genet 2007, 80:502-509.
14. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D, et al. Population genomics of human gene expression. Nat Genet 2007, 39:1217-1224.
15. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861.
16. Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, Morley M, Spielman RS. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet 2003, 33:422-425.
17. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS, Cheung VG. Genetic analysis of genome-wide variation in human gene expression. Nature 2004, 430:743-747.
18. Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH Jr, Badner JA. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 2004, 64:4353-4356.
19. Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol 2006, 1:119-128.
20. Jones TS, Yang W, Evans WE, Relling MV. Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Clin Pharmacol Ther 2007, 81:729-734.
21. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010, 11:493-496.
22. Gamazon Eric R, Ziliak D, Im Hae K, LaCroix B, Park Danny S, Cox Nancy J, Huang RS. Genetic architecture of MicroRNA expression: implications for the transcriptome and complex traits. Am J Hum Genet 2012, 90:1046-1063.
23. Fraser HB, Lam LL, Neumann SM, Kobor MS. Population-specificity of human DNA methylation. Genome Biol 2012, 13:R8.
24. Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Regi R, Degner JF, Gilad Y, Pritchard JK. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol 2011, 12:R10.
25. Moen LE, Mu W, Delaney S, Wing C, McQuade J, Godley LA, Dolan ME, Zhang W. Differences in DNA methylation between the African and European HapMap populations. Proc Am Assoc Cancer Res 2012:5010.
26. Huang R, Johnatty S, Gamazon E, Im H, Ziliak D, Duan S, Zhang W, Kistner E, Chen P, Beesley J, et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 2011, 17:5490-5500.
27. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008, 9:387-402.
28. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E, Khalili H, Damle A, Kern M, Furie R, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008, 14:575-581.
29. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, et al. HLA-B[ast]5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 41:816-819.
30. Volpi S, Heaton C, Mack K, Hamilton JB, Lannan R, Wolfgang CD, Licamele L, Polymeropoulos MH, Lavedan C. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2008, 14:1024-1031.
31. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, Lannan R, Thompson A, Wolfgang CD, Polymeropoulos MH. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2008, 14:804-819.
32. Adkins DE, Aberg K, McClay JL, Bukszar J, Zhao Z, Jia P, Stroup TS, Perkins D, McEvoy JP, Lieberman JA, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2011, 16:321-332.
33. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology 2009, 206:491-499.
34. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, Lieberman JA, Sullivan PF, van den Oord EJCG. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011, 16:76-85.
35. Uher R, Perroud N, Ng M, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010, 167:555-564.
36. Garriock H, Kraft J, Shyn S, Peters E, Yokoyama J, Jenkins G, Reinalda M, Slager S, McGrath P, Hamilton S. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010, 67:133-138.
37. Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS, Sicotte H, Kocher J-P, Rodin AS, Boerwinkle E. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 2008, 52:359-365.
38. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension 2012, 59:1204-1211.
39. Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011, 43:117-120.
40. Barber M, Mangravite L, Hyde C, Chasman D, Smith J, McCarty C, Li X, Wilke R, Rieder M, Williams P, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One 2010, 5:e9763.
41. Uhl G, Drgon T, Johnson C, Walther D, David S, Aveyard P, Murphy M, Johnstone E, Munafò M. Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics 2010, 11:357-367.
42. Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A, Zavras AI. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 2012, 17:279-287.
43. Ramsey LB, Bruun GH, Yang W, Treviño LR, Vattathil S, Scheet P, Cheng C, Rosner GL, Giacomini KM, Fan Y, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2012, 22:1-8.
44. Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird N, Katori N, Saito Y, Ohnami S, Sakamoto H, et al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 2011, 6:132-138.
45. Tantisira K, Lasky-Su J, Harada M, Murphy A, Litonjua A, Himes B, Lange C, Lazarus R, Sylvia J, Klanderman B, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011, 365:1173-1183.
46. Himes B, Jiang X, Hu R, Wu A, Lasky-Su J, Klanderman B, Ziniti J, Senter-Sylvia J, Lima J, Irvin C, et al. Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene. PLoS Genet 2012, 8:e1002824.
47. SEARCH Collaborative Group; Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008, 359:789-799.
48. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
49. Nicolae D, Gamazon E, Zhang W, Duan S, Dolan M, Cox N. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 2010, 6:e1000888.
50. Manolio T, Green E. Genomics reaches the clinic: from basic discoveries to clinical impact. Cell 2011, 147:14-16.
51. Huang R, Ratain M. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009, 59:42-55.
52. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, et al. The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012, 92:112-117.
53. Heart Protection Study Collaborative G. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20536 high-risk individuals: a randomised controlled trial. Lancet 2011, 378:2013-2020.
54. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. The SLCO1B1 5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616.
55. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJD, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012, 12:233-237.
56. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, Molina M, Niemi M, Schwab M, Somogyi A, et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 2011, 12:113-124.
57. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MTM, Pirmohamed M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011, 90:625-629.
58. Shehab N, Sperling L, Kegler S, Budnitz D. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med 2010, 170:1926-1933.
59. Higashi M, Veenstra D, Kondo L, Wittkowsky A, Srinouanprachanh S, Farin F, Rettie A. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287:1690-1698.
60. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353:717-719.
61. Rieder M, Reiner A, Gage B, Nickerson D, Eby C, McLeod H, Blough D, Thummel K, Veenstra D, Rettie A. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352:2285-2293.
62. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008, 112:1022-1027.
63. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5:e1000433.
64. Cha P-C, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, Nakamura Y. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010, 19:4735-4744.
65. Gage B, Lesko L. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008, 25:45-51.
66. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008, 84:326-331.
67. International Warfarin Pharmacogenetics Consortium; Klein T, Altman R, Eriksson N, Gage B, Kimmel S, Lee M, Limdi N, Page D, Roden D, Wagner MJ, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360:753-764.
68. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SFS, May HT, Samuelson KM, Muhlestein JB, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116:2563-2570.
69. Epstein RS, Moyer TP, Aubert RE, Okane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR. Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). J Am Coll Cardiol 2010, 55:2804-2812.